Hypermarcas (OTCMKTS:HYPMY) Short Interest Update

Hypermarcas (OTCMKTS:HYPMY) was the target of a significant decrease in short interest in the month of July. As of July 31st, there was short interest totaling 3,256 shares, a decrease of 43.9% from the July 15th total of 5,807 shares. Based on an average daily trading volume, of 19,962 shares, the short-interest ratio is currently 0.2 days. Approximately 0.0% of the company’s shares are short sold.

Analysts Set New Price Targets

HYPMY has been the topic of several recent analyst reports. Zacks Research raised Hypermarcas to a “hold” rating in a research note on Wednesday, April 29th. Jefferies Financial Group upgraded Hypermarcas to a “strong-buy” rating in a research report on Monday, July 20th. One research analyst has rated the stock with a Strong Buy rating and one has assigned a Hold rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Buy”.

Hypermarcas Stock Down 3.6%

Shares of HYPMY opened at $3.99 on Wednesday. The firm has a 50 day moving average of $4.09 and a 200 day moving average of $4.33. Hypermarcas has a twelve month low of $3.71 and a twelve month high of $5.50. The company has a market capitalization of $2.81 billion, a P/E ratio of 7.98 and a beta of 0.70.

Hypermarcas (OTCMKTS:HYPMY) last released its quarterly earnings data on Thursday, August 6th. The company reported $0.14 EPS for the quarter, topping the consensus estimate of $0.13 by $0.01. Hypermarcas had a return on equity of 14.63% and a net margin of 19.77%. On average, sell-side analysts expect that Hypermarcas will post 0.53 EPS for the current year.

Hypermarcas Company Profile

Hypermarcas SA is a Brazil-based consumer health and pharmaceutical company whose shares trade over the counter in the United States under the symbol HYPMY. Founded in the early 2000s and headquartered in Rio de Janeiro, the company operates as a holding group for a broad portfolio of branded products in the healthcare and personal care sectors.

Through its various subsidiaries, Hypermarcas develops, manufactures and markets prescription and over-the-counter medications, alongside personal care, baby care, home care and nutritional supplement products.